logo-loader
viewPhagoMed Biopharma

PhagoMed looks to raise around $18M to scale up its bacterial infections treatment

PhagoMed Biopharma GmbH CEO Alexander Belcredi spoke with Proactive at the Biotech Showcase 2020 in San Francisco. The Austria-based biotech's pipeline is focused on treating biofilm-forming bacterial infections, which are all in preclinical development. The company specializes in fighting multi-resistant bacteria, where multiple antibiotics have become ineffective.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Pure Gold adds 12.3 million dollars to treasury bringing...

Pure Gold (CVE: PGM) CEO Darin Labrenz updated Steve Darling from Proactive Vancouver that the company has exercised 14,465 million share warrants raising 12.3 million dollars. With that capital added, the treasury now has over 100 million dollars. In fact, the company now sits with 150 million...

40 minutes ago

2 min read